The U.S. Supreme Court has extended access to the widely used abortion pill mifepristone until at least Thursday, granting an administrative stay that gives justices more time to consider an emergency request to halt a lower court ruling that would restrict access to the drug.
Justice Samuel Alito had issued an initial halt last week that was due to expire Monday night. The court's administrative stay means healthcare providers can continue prescribing mifepristone via telemedicine and deliver it through the mail while the justices deliberate.
The underlying case stems from a challenge to federal approval of mifepristone, which has been used by millions of American women for medication abortion since its FDA approval in 2000. Lower courts have issued conflicting rulings on whether the drug's approval should be rolled back or modified.
What the Left Is Saying
Abortion rights advocates praised the court's action as a necessary intervention to protect access to time-sensitive healthcare. Groups including Planned Parenthood and the Guttmacher Institute, which tracks reproductive health data, have argued that restricting mifepristone would cause significant harm to patients, particularly those in rural areas who rely on mail-order pharmacy services.
Senator Tina Smith of Minnesota said in a statement that the stay "buys precious time for millions of women who depend on this medication." She added that any rollback of mifepristone access would be "a direct attack on the healthcare decisions of American families."
The American College of Obstetricians and Gynecologists filed an amicus brief in the case, arguing that mifepristone is safe and effective and that restricting it would force patients to seek more invasive procedures. "Medication abortion accounts for over half of all abortions performed in the United States," the group noted.
What the Right Is Saying
Opponents of broad mifepristone access argue that the FDA improperly approved the drug and that courts have a duty to review agency actions they consider unlawful. Groups including Students for Life of America and the Susan B. Anthony Pro-Life America have pushed for stricter regulations on abortion medication.
Senator Josh Hawley of Missouri said the Supreme Court should use this time to "fully examine whether the FDA followed proper procedures" when it approved mifepristone decades ago. He has previously introduced legislation that would require in-person dispensing of the drug.
Alliance Defending Freedom, a conservative legal organization representing plaintiffs in the underlying case, argued that courts must ensure federal agencies operate within their statutory authority. "The FDA does not get to ignore safety concerns simply because a medication is widely used," the group stated in court filings.
What the Numbers Show
Mifepristone has been FDA-approved since 2000 and is used in approximately 63% of all abortions performed in the United States, according to Guttmacher Institute data from 2023. The medication is approved for use up to 10 weeks gestation.
The drug was involved in more than 5 million legal abortions between 2000 and 2022, according to FDA reporting requirements. Adverse events are rare, occurring in fewer than 1% of patients who take the medication as prescribed.
A 2024 Kaiser Family Foundation survey found that 57% of American adults believe mifepristone should remain available in its current form, while 21% support restricting it and 22% expressed no opinion. Support for access was higher among Democrats (79%) than Republicans (35%).
The Bottom Line
The Supreme Court's stay delays any change to mifepristone access at least until Thursday, when the justices are expected to issue a more definitive ruling on whether to hear the full case or let the current FDA approvals stand. Legal experts say the court could ultimately decide the case on narrower procedural grounds rather than the substantive questions about FDA authority.
What happens next depends on whether the justices agree to take up the appeal and how they rule on the merits of the challenge. If the Supreme Court declines to hear the case, lower court rulings restricting mifepristone access in certain states could take effect. If the court takes the case and rules for the challengers, medication abortion protocols across the country could be significantly altered.